In lung adenocarcinoma, immunohistochemical assessments of Met protein expression have revealed that Met is an independent predictor of a poor prognosis16, but its expression has not been revealed to be a prognostic and/or predictive marker of the effects of anti-MET/HGF therapeutics in a large high-grade glioma population. This evidence concerns the gene MET and central nervous system cancer.